ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

DTIL Precision BioSciences Inc

12.65
-0.09 (-0.71%)
28 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Precision BioSciences Inc DTIL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.09 -0.71% 12.65 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
12.94 12.27 12.98 12.65 12.74
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/5/202406:00BWPrecision BioSciences Announces Grant of Inducement Awards..
13/5/202406:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202406:15EDGAR2Form 8-K - Current report
13/5/202406:00BWPrecision BioSciences Reports First Quarter 2024 Financial..
08/5/202419:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202419:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202419:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202419:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202407:19EDGAR2Form 8-K - Current report
08/5/202407:15BWPrecision BioSciences Announces Common Stock Purchase by..
07/5/202415:30BWPrecision BioSciences to Report First Quarter Results on May..
07/5/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202407:30BWPrecision BioSciences Announces Receipt of FDA Fast Track..
01/5/202406:05BWPrecision BioSciences Announces Late-Breaking Poster..
16/4/202415:15BWPrecision BioSciences Announces Return of Programs and..
27/3/202405:45BWPrecision BioSciences Reports Fourth Quarter and Fiscal Year..
20/3/202415:30BWPrecision BioSciences to Report Fourth Quarter and Fiscal..
19/3/202406:00BWPrecision BioSciences Presents Preclinical Data Highlighting..
06/3/202407:45BWPrecision BioSciences Announces MHRA Approval for Partner..
01/3/202407:00EDGAR2Form 8-K - Current report
01/3/202405:30BWPrecision BioSciences Announces $40.0 Million Offering of..
01/3/202405:00EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
29/2/202416:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202415:01BWPrecision BioSciences Announces Proposed Public Offering of..
20/2/202406:00BWPrecision BioSciences Announces Non-Exclusive Patent License..
14/2/202406:00BWPrecision BioSciences Receives Pre-IND Feedback from US FDA..
13/2/202407:29EDGAR2Form 8-K - Current report
13/2/202406:00BWPrecision BioSciences Promotes Naresh Tanna to Vice..
12/2/202410:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202406:00BWPrecision BioSciences Receives Initial $7.5 Million Cash..
09/2/202406:00BWPrecision BioSciences to Effect a Reverse Stock Split
23/1/202418:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202418:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202418:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202418:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202418:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202416:29EDGAR2Form 8-K - Current report
23/1/202415:27EDGAR2Form 144 - Report of proposed sale of securities
22/1/202414:46EDGAR2Form 144 - Report of proposed sale of securities
22/1/202414:42EDGAR2Form 144 - Report of proposed sale of securities
22/1/202414:42EDGAR2Form 144 - Report of proposed sale of securities
19/1/202406:30EDGAR2Form 8-K - Current report
12/1/202407:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/1/202407:31EDGAR2Form 8-K - Current report
09/1/202408:20APSBiotech Massively Bid Up Before Opening Bell

Su Consulta Reciente